EGI
KNSA icon

EAM Global Investors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

EAM Global Investors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-116,864
Closed -$1.75M – 142
2022
Q4 		$1.75M Buy
+116,864
New +$1.7M 0.45% 109

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

EAM Global Investors's KNSA Position: Q1 2023 in Review

EAM Global Investors sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2023, closing a stake of 116,864 shares — an estimated $1.75M sold.

EAM Global Investors first reported a position in KNSA in Q4 2022 and held it in 1 quarter. The position peaked at $1.75M in Q4 2022. 132 funds tracked by Wall St. Rank hold KNSA as of Q1 2023.

  • EAM Global Investors reported no remaining Kiniksa Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 116,864 Kiniksa Pharmaceuticals shares in Q1 2023, an estimated $1.75M.
  • EAM Global Investors first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • EAM Global Investors's Kiniksa Pharmaceuticals position peaked at $1.75M in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.